IFNA1 and depressive symptom measurement: Beyond IFN-α treatment, the identified transcriptomics signatures could be used as biomarkers for the identification of individuals at risk of developing depression, especially in the context of high inflammation due to stress, physical illness, or genetic make-up, or to generate molecular targets for the discovery of new therapeutics in depression.